POP BIO and CEPI Collaborate for Faster COVID-19 Vaccine Development
POP Biotechnologies Announces Collaboration with CEPI to Advance Vaccine Development
Table of Contents
POP Biotechnologies and CEPI Forge Strategic Alliance to Accelerate Vaccine Innovation
Buffalo, NY – July 25, 2025 – POP Biotechnologies, Inc., a pioneering biotechnology firm renowned for its innovative porphyrin-phospholipid (PoP) liposome technology, today announced a notable collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI). This partnership aims to leverage POP BIO’s proprietary SNAP™ technology to expedite the development and equitable access of novel vaccines against emerging infectious disease threats.
POP Bio Staff Scientists Dr. Hilliard Kutscher and Matthew Willadsen
About POP Biotechnologies
POP Biotechnologies, Inc.is a privately held biotechnology company dedicated to creating groundbreaking therapeutics and vaccines. At the heart of its innovation is the proprietary porphyrin-phospholipid (PoP) liposome technology. this cutting-edge platform,exclusively licensed from the State University of New York research Foundation (SUNY-RF),was originally developed by co-founder dr.Jonathan Lovell at SUNY Buffalo. POP Biotechnologies proudly operates from the SUNY Buffalo incubator, situated within the vibrant Baird Research Park, fostering a collaborative surroundings for scientific advancement.
POP BIO’s SNAP™ Technology: A leap Forward in Vaccine Design
The core of this collaboration lies in POP BIO’s revolutionary SNAP™ (Spontaneous Nanoliposome Antigen Particleization) technology. This innovative platform utilizes a cobalt-modified PoP liposome system, known as CoPoP, to enable the rapid development of highly potent particle-based vaccines. SNAP™ facilitates the stable, spontaneous display of protein and peptide antigens on liposomes, a process that substantially boosts immunogenicity.The efficacy and safety of POP BIO’s SNAP™ technology have already been validated, demonstrating favorable safety and immunogenicity profiles in Phase 3 trials for the EuCorVac-19 COVID-19 vaccine. This proven track record positions SNAP™ as a powerful tool for addressing future health crises.
CEPI: Leading the Charge Against Epidemics
CEPI, established in 2017, stands as a testament to innovative global collaboration.Bringing together public, private, philanthropic, and civil organizations, CEPI’s basic mission is to accelerate the development of vaccines and other biological countermeasures against epidemic and pandemic disease threats. Crucially, CEPI is committed to ensuring equitable access to these vital innovations worldwide. To date,CEPI has championed the development of over 50 vaccine candidates and platform technologies targeting a range of high-risk pathogens.Moreover, CEPI is actively advancing rapid response platforms designed to combat future Disease X threats. A cornerstone of CEPI’s ambitious five-year plan (2022-2026) is the ’100 Days Mission,’ an initiative focused on drastically reducing the timeline for developing safe, effective, and globally accessible vaccines against new threats to a mere 100 days.
This partnership between POP Biotechnologies and CEPI signifies a shared commitment to bolstering global health security and preparedness. By combining POP BIO’s advanced SNAP™ technology with CEPI’s extensive expertise and global reach, the collaboration is poised to make significant strides in developing rapid, effective, and accessible vaccines for the world.
Press Inquiries
Jonathan R Smyth
POP Biotechnologies, Inc.
+1 315-220-0087
jrsmyth@popbiotech.com
Visit us on social media:
LinkedIn
